{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:01:31Z","timestamp":1792119691058,"version":"4.4.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"name":"National Institute of Health","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    Point mutations in genes of the mitogen-activated protein kinase (MAPK) pathway are the most frequent oncogenic drivers of melanocytic neoplasms, whereas gene fusions are comparatively rare. Kinase fusions are among the molecular alterations that characterize Spitz neoplasms; however, not all melanocytic tumors that harbor one as the main oncogenic driver conform to clinical and\/or histomorphologic parameters associated with Spitz neoplasms. In this study, we describe the clinical, histopathologic, and molecular characteristics of 7\n                    <jats:italic toggle=\"yes\">RAF1<\/jats:italic>\n                    and 23\n                    <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                    fusion-positive melanomas of patients who presented with or later developed regional and\/or distant metastases. We report that most tumors in this series arose in adult patients and lacked Spitz-like microscopic features. Awareness of the varied clinical and histopathologic presentation of\n                    <jats:italic toggle=\"yes\">RAF1<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                    fusion-positive melanomas is important as the protein products of these kinase gene fusions constitute potentially actionable therapeutic targets.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002476","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:00:48Z","timestamp":1760698848000},"page":"103-117","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Clinicopathogenomic Characteristics of Primary and Metastatic Melanomas With RAF1 and BRAF Fusions"],"prefix":"10.1097","volume":"50","author":[{"given":"Cecilia","family":"Lezcano","sequence":"first","affiliation":[{"name":"Dermatopathology, Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel S.","family":"Kasago","sequence":"additional","affiliation":[{"name":"Diagnostic Molecular Pathology, Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Tang","sequence":"additional","affiliation":[{"name":"Dermatopathology, Department of Pathology and Laboratory Medicine"},{"name":"Diagnostic Molecular Pathology, Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Febres-Aldana","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Benhamida","sequence":"additional","affiliation":[{"name":"Diagnostic Molecular Pathology, Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N.","family":"Shoushtari","sequence":"additional","affiliation":[{"name":"Melanoma Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica F.","family":"Chen","sequence":"additional","affiliation":[{"name":"Melanoma Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus J.","family":"Busam","sequence":"additional","affiliation":[{"name":"Dermatopathology, Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"R1-20251215","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 World Health Organization Classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"R2-20251215","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat Commun"},{"key":"R3-20251215","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Cancer Genome Atlas N. Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"key":"R4-20251215","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat Commun"},{"key":"R5-20251215","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/PAS.0000000000000761","article-title":"A comparison of morphologic and molecular features of BRAF, ALK, and NTRK1 fusion Spitzoid neoplasms","volume":"41","author":"Amin","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R6-20251215","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/PAS.0000000000001070","article-title":"Primary and metastatic melanoma with NTRK fusions","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R7-20251215","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1038\/ncomms8174","article-title":"Activating MET kinase rearrangements in melanoma and Spitz tumours","volume":"6","author":"Yeh","year":"2015","journal-title":"Nat Commun"},{"key":"R8-20251215","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/path.4775","article-title":"NTRK3 kinase fusions in Spitz tumours","volume":"240","author":"Yeh","year":"2016","journal-title":"J Pathol"},{"key":"R9-20251215","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.modpat.2023.100149","article-title":"Spectrum of melanocytic tumors harboring BRAF gene fusions: 58 cases with histomorphologic and genetic correlations","volume":"36","author":"Roy","year":"2023","journal-title":"Mod Pathol"},{"key":"R10-20251215","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/s41379-020-0510-7","article-title":"Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles","volume":"33","author":"Williams","year":"2020","journal-title":"Mod Pathol"},{"key":"R11-20251215","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41591-019-0373-y","article-title":"Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas","volume":"25","author":"Newman","year":"2019","journal-title":"Nat Med"},{"key":"R12-20251215","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/pcmr.12148","article-title":"Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy","volume":"26","author":"Botton","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"R13-20251215","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1097\/PAS.0000000000002302","article-title":"The clinical, morphologic, and molecular spectrum of BRAF fusion Spitz tumors","volume":"48","author":"Sharma","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"R14-20251215","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/s41379-022-01138-z","article-title":"Identification of fusions with potential clinical significance in melanoma","volume":"35","author":"Moran","year":"2022","journal-title":"Mod Pathol"},{"key":"R15-20251215","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.celrep.2019.09.009","article-title":"Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses","volume":"29","author":"Botton","year":"2019","journal-title":"Cell Rep"},{"key":"R16-20251215","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"R17-20251215","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"R18-20251215","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"R19-20251215","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/his.14583","article-title":"Spitz melanocytic tumours - a review","volume":"80","author":"Yeh","year":"2022","journal-title":"Histopathology"},{"key":"R20-20251215","doi-asserted-by":"crossref","first-page":"oyae297","DOI":"10.1093\/oncolo\/oyae297","article-title":"Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma","volume":"30","author":"Khaddour","year":"2025","journal-title":"Oncologist"},{"key":"R21-20251215","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/2159-8290.CD-24-0139","article-title":"The Pan-RAF-MEK nondegrading molecular glue NST-628 is a potent and brain-penetrant inhibitor of the RAS-MAPK pathway with activity across diverse RAS- and RAF-driven cancers","volume":"14","author":"Ryan","year":"2024","journal-title":"Cancer Discov"},{"key":"R22-20251215","doi-asserted-by":"crossref","first-page":"S492","DOI":"10.1016\/j.annonc.2024.08.681","article-title":"Type II RAF inhibitor tovorafenib in recurrent\/refractory (R\/R) melanoma or other solid tumors with RAF fusions and\/or RAF1 amplification","volume":"35","author":"Vieito","year":"2024","journal-title":"Ann Oncol"},{"key":"R23-20251215","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/DAD.0000000000003048","volume":"47","author":"Cho","year":"2025","journal-title":"Am J Dermatopathol"},{"key":"R24-20251215","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/DAD.0000000000002936","article-title":"Melanoma With RNF11::BRAF fusion: a novel fusion previously undescribed in melanoma","volume":"47","author":"Gao","year":"2025","journal-title":"Am J Dermatopathol"},{"key":"R25-20251215","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/cup.14704","article-title":"Histopathologic, genomic, transcriptomic, and functional characteristics of eight melanocytic tumors with BRAF fusions showing stronger MAPK pathway activation compared to BRAF V600E tumors","volume":"51","author":"Li","year":"2024","journal-title":"J Cutan Pathol"},{"key":"R26-20251215","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/1346-8138.17187","article-title":"Comparative transcriptomic analysis reveals differences in gene expression and regulatory pathways between nonacral and acral melanoma in Asian individuals","volume":"51","author":"Chiu","year":"2024","journal-title":"J Dermatol"},{"key":"R27-20251215","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-23-3981","article-title":"Tumor-agnostic genomic and clinical analysis of braf fusions identifies actionable targets","volume":"30","author":"Chen","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R28-20251215","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/bjd\/ljaf061","article-title":"Congenital melanocytic nevi initiated by BRAF fusion oncogene with firmness, pruritus, and desmoplastic stroma","volume":"193","author":"Roy","year":"2025","journal-title":"Br J Dermatol"},{"key":"R29-20251215","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00428-017-2290-0","article-title":"Unclassified sclerosing malignant melanomas with AKAP9-BRAF gene fusion: a report of two cases and review of BRAF fusions in melanocytic tumors","volume":"472","author":"Perron","year":"2018","journal-title":"Virchows Arch"},{"key":"R30-20251215","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/pde.14957","article-title":"Risk factors for the development of Spitz neoplasms","volume":"39","author":"Benton","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"R31-20251215","doi-asserted-by":"crossref","first-page":"e1009302","DOI":"10.1371\/journal.pgen.1009302","article-title":"UV-exposure, endogenous DNA damage, and DNA replication errors shape the spectra of genome changes in human skin","volume":"17","author":"Saini","year":"2021","journal-title":"PLoS Genet"},{"key":"R32-20251215","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41379-019-0445-z","article-title":"Spitz melanoma is a distinct subset of spitzoid melanoma","volume":"33","author":"Raghavan","year":"2020","journal-title":"Mod Pathol"},{"key":"R33-20251215","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jid.2023.06.213","article-title":"Mosaic BRAF fusions are a recurrent cause of congenital melanocytic nevi targetable by MAPK pathway inhibition","volume":"144","author":"Martin","year":"2024","journal-title":"J Invest Dermatol"},{"key":"R34-20251215","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/sj.jid.5700725","article-title":"Chromosomal translocations as a mechanism of BRAF activation in two cases of large congenital melanocytic nevi","volume":"127","author":"Dessars","year":"2007","journal-title":"J Invest Dermatol"},{"key":"R35-20251215","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jid.2018.07.045","article-title":"Genetic abnormalities in large to giant congenital nevi: beyond NRAS mutations","volume":"139","author":"Martins da Silva","year":"2019","journal-title":"J Invest Dermatol"},{"key":"R36-20251215","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/pcmr.12785","article-title":"Malignant melanoma with\u202fareas of\u202frhabdomyosarcomatous\u202fdifferentiation arising in a giant congenital nevus with RAF1 gene fusion","volume":"32","author":"Baltres","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"R37-20251215","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R38-20251215","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-13-1746","article-title":"BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition","volume":"19","author":"Hutchinson","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R39-20251215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00138","article-title":"Significant clinical response to a MEK inhibitor therapy in a patient with metastatic melanoma harboring an RAF1 fusion","volume":"2","author":"Kim","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"R40-20251215","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1172\/JCI123089","article-title":"Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion","volume":"129","author":"McEvoy","year":"2019","journal-title":"J Clin Invest"},{"key":"R41-20251215","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/pcmr.12388","article-title":"Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion","volume":"28","author":"Menzies","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"R42-20251215","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-20-4189","article-title":"Therapeutic implications of detecting MAPK-activating alterations in cutaneous and unknown primary melanomas","volume":"27","author":"Shoushtari","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R43-20251215","doi-asserted-by":"crossref","first-page":"A095","DOI":"10.1158\/1535-7163.TARG-23-A095","article-title":"Abstract A095: The paradox-breaker BRAF inhibitor plixorafenib (FORE8394) efficiently inhibits non-V600 mutations and fusions","volume":"22","author":"Cohen","year":"2023","journal-title":"Molecular Cancer Therapeutics"},{"key":"R44-20251215","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41591-018-0274-5","article-title":"RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling","volume":"25","author":"Yao","year":"2019","journal-title":"Nat Med"},{"key":"R45-20251215","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/CMR.0000000000000882","article-title":"Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene","volume":"33","author":"Boileau","year":"2023","journal-title":"Melanoma Res"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:03:03Z","timestamp":1765814583000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002476","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}